marginal cell
Recently Published Documents


TOTAL DOCUMENTS

52
(FIVE YEARS 2)

H-INDEX

11
(FIVE YEARS 0)

2021 ◽  
Vol 22 (3) ◽  
pp. 271-273
Author(s):  
Aqeel Hussain ◽  
◽  
Rajkrishnan Soman ◽  
Abhishek Goyal ◽  
Ujjawal Khurana ◽  
...  
Keyword(s):  

Cureus ◽  
2020 ◽  
Author(s):  
Ani Mnatsakanian ◽  
Suzanne Forman ◽  
Shant A Korkigian
Keyword(s):  

2020 ◽  
Author(s):  
Arash Dehghan ◽  
Nika Eskandari ◽  
Nakisa Niknejad

The description of histopathological features of spleen specimens in those are undergoing splenectomy is necessary and even vital for selecting the best patient's diagnostic and therapeutic management. However, in some cases, the histological findings of those with dramatic clinical presentation may be imperceptible and vice versa. What we did in the present study was to assess the clinical and histopathological findings as well as the main indications for splenectomy in a sample of Iranian affected population. This cross-sectional study was conducted on 616 spleen specimens following complete or partial splenectomy performed at pathology laboratory at Besat Hospital in Hamadan, Iran, between 2007 and 2017. Demographic characteristics, the main reasons for splenectomy, grading of trauma, and histopathological findings were retrospectively collected by reviewing the hospital recorded files and laboratory reports. The most common cause for splenectomy included trauma in 59.25%, followed by idiopathic thrombocytopenic purpura in 15.58% and symptomatic splenomegaly in 9.09%. The specimens were normal at 38.0%. Among those with lymphoma, the definitive diagnosis included diffused large B cell lymphoma in 42.85%, Hodgkin lymphoma in 42.85%, Follicular cell lymphoma in 9.52%, and Marginal cell lymphoma in 4.76%. Trauma and idiopathic thrombocytopenic purpura are the most common indications for splenectomy. Given the normality of the pathologic findings in more than one-third of patients undergoing splenectomy, closer attention to indications for this procedure through further evaluation of patients and predicting the outcome of the procedure is necessary.


CHEST Journal ◽  
2020 ◽  
Vol 158 (4) ◽  
pp. A1636
Author(s):  
Muhammad Danial Siddiqui ◽  
Touba Naim ◽  
Muhammad Hamza ◽  
Travis Hanson

Orbit ◽  
2020 ◽  
pp. 1-5
Author(s):  
Sitara H. Hirji ◽  
Michelle M. Maeng ◽  
Andrea A. Tooley ◽  
Craig Soderquist ◽  
Joseph Annunziata ◽  
...  

2017 ◽  
Vol 2 (1) ◽  
pp. 65-67
Author(s):  
Havall M Amin ◽  
Nabeel A. Mawlood

A New species of the family Apidae, Anthophora sulaimanensis sp. nov. Is described; main parts illustrated and got comparisons with its nearly- related species from Iraq-Kurdistan region. The species is characterized by   Mandibles black, bi dentate; Labrum black  with two brown sculptures on lateral basal sides; Clypeus without sculpture; Marginal cell of the fore wings broadly rounded apically, strongly bent away from wing margin. The important taxonomic parts have been drawn. Localities, plant visiting and collections date     have been mentioned.


2016 ◽  
Vol 35 (4) ◽  
pp. 327-332 ◽  
Author(s):  
Francesca Magnoli ◽  
Laura Cimetti ◽  
Barbara Bernasconi ◽  
Nora Sahnane ◽  
Isabella Redaelli ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Salwa Hussain ◽  
Ruby Jhaj ◽  
Samira Ahsan ◽  
Muhammad Ahsan ◽  
Robert E. Bloom ◽  
...  

Background. It has recently been reported that hepatitis B (HBV) reactivation often occurs after the use of rituximab and stem cell transplantation in patients with lymphoma who are hepatitis B surface antigen (HBsAg) negative. However, clinical data on HBV reactivation in multiple myeloma (MM) is limited to only a few reported cases. Bortezomib and lenalidomide have remarkable activity in MM with manageable toxicity profiles, but reactivation of viral infections may emerge as a problem. We present a case of MM that developed HBV reactivation after bortezomib and lenalidomide therapy.Case Report. A 73-year-old female with a history of marginal cell lymphoma was monitored without requiring therapy. In 2009, she developed MM, presenting as a plasmacytoma requiring vertebral decompression and focal radiation. While receiving radiation she developed renal failure and was started on bortezomib and liposomal doxorubicin. After a transient response to 5 cycles, treatment was switched to lenalidomide. Preceding therapy initiation, her serology indicated resolved infection. Serial monitoring for HBV displayed seroconversion one month after change in therapy.Conclusion. Bortezomib associated late HBV reactivation appears to be a unique event that requires further confirmation and brings to discussion whether hepatitis B core positive individuals would benefit from monitoring of HBV activation while on therapy.


Sign in / Sign up

Export Citation Format

Share Document